Recruiting NCT07701161
Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Alzheimer s Disease, MCI Conversion to Dementia, pTau217, Biomarkers. Basic parameters: 40 years — 90 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.
Primary outcome measures
- Agreement between p-tau217 concentration in Tasso device capillary blood and venipuncture blood [Time frame: Baseline]
Eligibility criteria
Inclusion criteria
- AD Amyloid PET/CSF confirmed, healthy control, or amyloid-negative non-AD cognitive impairment Age 40-90 Able to complete Tasso and venipuncture collection Caregiver consent/assistance available if needed
Exclusion criteria
- Uncontrolled systemic conditions Recent surgery/hospitalization (3 months) Other dementia drug trial (2 months) Pregnancy Prior Donanemab or Lecanemab use
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
United States · 5 centers
- Insigth Hospital and Medical Center Chicago — Chicago
- Insight Hospital and Medical Center Dearborn — Dearborn
- Insight Institute of Neurology and Neurosurgery — Flint
- Memorial Healthcare Hospital — Owosso
- Wake Forest Baptist Medical Center — Winston-Salem
Identifiers
NCT: NCT07701161 · Neurogen-12951